Sofosbuvir / Velpatasvir bulk supplier for pharma manufacturers

Sofosbuvir / Velpatasvir Suppliers & Bulk Manufacturers

Available Forms: Tablet

Available Strengths: Sofosbuvir 400 mg + Velpatasvir 100 mg

Reference Brands: Epclusa (EU & US)

Category: Hepatitis

Sofosbuvir 400 mg + Velpatasvir 100 mg Tablets (Epclusa® generic) are used to treat all major HCV genotypes. Manufactured under EU-GMP/USFDA compliance, ideal for B2B supply, tenders, and licensing with full CTD and regulatory support.

Get Enquiry / Request Bulk Quote

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Sofosbuvir / Velpatasvir? List it or send an offer →

Product Description:

Sofosbuvir 400 mg + Velpatasvir 100 mg tablets (Epclusa® generic) are oral antivirals indicated for pan-genotypic Hepatitis C treatment. This once-daily fixed-dose combination is effective across all major HCV genotypes and offers high SVR rates. Manufactured under EU-GMP and USFDA-approved facilities, the product is available for B2B supply, tenders, and contract manufacturing. Regulatory support includes CTD dossiers and bioequivalence studies. Widely accepted across EU, US, LATAM, and MENA markets, Sofosbuvir + Velpatasvir is a key addition to antiviral portfolios targeting global Hepatitis C elimination goals.

Sofosbuvir / Velpatasvir — third party manufacturing & bulk supply

Sofosbuvir / Velpatasvir is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Sofosbuvir / Velpatasvir is supplied as Tablet — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Sofosbuvir / Velpatasvir listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Sofosbuvir / Velpatasvir →

Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.

Back to Listing

Frequently Asked Questions

Sofosbuvir / Velpatasvir is used for the treatment of chronic hepatitis C virus (HCV) infection across all major genotypes (1 to 6). It helps reduce viral load and can achieve sustained virologic response (SVR), effectively curing the infection in most patients.

Sofosbuvir is a nucleotide analog NS5B polymerase inhibitor, and Velpatasvir is an NS5A inhibitor. Together, they work by blocking different stages of the hepatitis C virus replication process.

The primary trade name is Epclusa, along with multiple generic brands such as Velpanat, Myhep All, SoviHep V, and Sofosvel available in different regions.

It is made by a number of companies in different countries, including India. We match each enquiry with licensed makers that can supply your market.

The generic name is Sofosbuvir 400 mg + Velpatasvir 100 mg.

Brand names include Epclusa, Velpanat, Myhep All, SoviHep V, and Sofosvel.

It is manufactured in multiple countries including the United States (by Gilead Sciences) and widely in India by leading pharmaceutical companies for global export markets.